Cancer is a word filled with foreboding, but this marvelous book by two distinguished oncologists explains its mysteries in lucid, straightforward language that allays fears and puts the disease clearly into perspective. Some 55% of the more serious internal cancers can now be cured with modern, multi disciplanary treatment and early diagnosis. ...

In Explaining Cancer, Anya Plutynski addresses a variety of philosophical questions that arise in the context of cancer science and medicine. She begins with the following concerns: · How do scientists classify cancer? Do these classifications reflect nature's "joints"? · How do cancer scientists identify and classify early stage cancers? · What does it mean to say that cancer is a "genetic" disease? What role do genes play in "mechanisms for" cancer? · What are the most important environmental causes of cancer, and how do epidemiologists investigate these causes? · How exactly has our evolutionary history made us vulnerable to cancer? Explaining Cancer uses these questions as an entrée into a family of philosophical debates. It uses case studies of scientific practice to reframe philosophical debates about natural classification in science and medicine, the problem of drawing the line between disease and health, mechanistic reasoning in science, pragmatics and evidence, the roles of models and modeling in science, and the nature of scientific explanation.

This collection of 25 research papers comprised of 22 original articles and 3 reviews is brought together from international leaders in bioinformatics and biostatistics. The collection highlights recent computational advances that improve the ability to analyze highly complex data sets to identify factors critical to cancer biology. Novel deep learning algorithms represent an emerging and highly valuable approach for collecting, characterizing and predicting clinical outcomes data. The collection highlights several of these approaches that are likely to become the foundation of research and clinical practice in the future. In fact, many of these technologies reveal new insights about basic cancer mechanisms by integrating data sets and structures that were previously immiscible. Accordingly, the series presented here bring forward a wide range of artificial intelligence approaches and statistical methods that can be applied to imaging and genomics data sets to identify previously unrecognized features that are critical for cancer. Our hope is that these articles will serve as a foundation for future research as the field of cancer biology transitions to integrating electronic health record, imaging, genomics and other complex datasets in order to develop new strategies that improve the overall health of individual patients.

This fully updated and revised new edition provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in prostate cancer. The book reviews new data about molecular characteristics of the disease, profiles the new grading system for prostate cancer introduced in 2015, and provides new perspectives about imaging of prostate cancer, as well as the role of targeted biopsies. The text summarizes the role of biomarkers and MRI in patient selection and management and details the world wide results of active surveillance. Specific chapters address communication and ethical issues, QOL outcomes, economic aspects, and psycho-social aspects of surveillance. The role of focal therapy for low risk disease is summarized, and the data supporting preventive interventions during surveillance reviewed. This text will serve as a very useful resource for physicians and researchers dealing with, and interested in this common malignancy, as it provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts.

This volume LNCS 14243 constitutes the refereed proceedings of the Second International Workshop, CMMCA 2023, Held in Conjunction with MICCAI 2023, on October 8, 2023, in Vancouver, BC, Canada. The 17 full papers presented were carefully reviewed and selected from 25 submissions. The conference focuses on the discovery of cutting-edge techniques addressing trends and challenges in theoretical, computational, and applied aspects of mathematical cancer data analysis.

Originally published by Oxford in 1998, Psycho-Oncology was the first comprehensive text in the field and remains the gold standard today. Edited by a team of leading experts in psycho-oncology, spearheaded by Dr. Jimmie C. Holland, the founder of the field, the text reflects the interdisciplinary nature and global reach of this growing field. Thoroughly updated and developed in collaboration with the American Psychosocial Society and the International Psycho-oncology Society, the third edition is a current, comprehensive reference for psychiatrists, psychologists, oncologists, hospice workers, and social workers seeking to understand and manage the psychological issues involved in the care of persons with cancer and the psychological, social, and behavioral factors that contribute to cancer risk and survival. New to this edition are chapters on gender-based and geriatric issues and expanded coverage of underserved populations, community based programs, and caregiver training and education.

Now in its seventh edition, this highly-regarded book is designed as an introductory and reference text on the principles of diagnosis, staging, and treatment of tumors. As for the last 6 editions of the book, the aim and scope of the new edition are once again to provide a thorough yet reasonably brief account of the whole field of oncology, focusing on the latest principles of cancer management. The book is already well established, having been first published in 1986 and in continuous print since then. The authors are rightfully proud of their strong legacy of providing carefully revised new editions of this standard and well-received cancer text for audiences in the UK and abroad. Oncology is a very rapidly changing speciality, with many new treatments and even treatment modalities coming on stream with bewildering speed. Besides a thorough general updating of the text, figures, and tables, the new seventh edition adds a new chapter on Molecular Targeted Therapy, making the book 30 chapters in total. This accessible and practical resource is invaluable to trainees and specialists alike in oncology, palliative care and general medicine, as well as specialist nurses, general practitioners, medical students, and professions allied to medicine.